maximum for targets, which included a mid-frontal P3a source, particularly for novels. As expected, a distinct FRN was seen for targets, with a peak latency of about 50-ms after the mean response latency (Table 2; cf. Kayser et al., 2007). Finally, a high-variance factor (935), with a peak latency near the end of the recording epoch, accounted for unsystematic variance associated with the baseline correction procedure (Kayser & Tenke, 2003). Almost identical topographies were observed for CHR patients and healthy controls (see supplementary Fig. S1).
